Sponsor Dossier
Eli Lilly
Sponsor Dossier for Eli Lilly. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ADCIRCA
- Brand: ALIMTA
- Brand: BASAGLAR
- Brand: CIALIS
- Brand: CYRAMZA
- Brand: EBGLYSS
- Brand: EMGALITY
- Brand: HUMALOG
- Device (sponsor): Basic insulin pen, replaceable-cartridge
About
Eli Lilly Australia Pty Ltd is an Australian Private Company with ABN 39 000 233 992, registered in NSW. The entity is active and registered for GST.
Portfolio
Eli Lilly has 18 brands on the ARTG, with 18 indexable brands and 16 brands with Product Information on file. Seven brands have at least one PBS-listed item, 16 brands have PBAC outcome records, and 11 brands have AusPAR records.
Therapeutic focus —
Oncology: 5 brands — Endocrinology: 4 brands — Immunology: 3 brands — Neurology: 2 brands — Cardiology: 2 brands — Urology: 1 brand — Dermatology: 1 brand
PBS footprint
Seven brands in the Eli Lilly portfolio have at least one PBS-listed item, with the portfolio's latest PBS schedule date being 1 May 2026.
Regulatory activity
Eli Lilly's most recent PBAC outcome was issued on 1 July 2025, with 16 brands on record having PBAC outcomes. The most recent AusPAR was issued on 26 September 2023, with 11 brands on record having AusPARs.